Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting pipeline of new medicines.” Isomorphic Labs, the UK-based biotech spinoff of ...

JavaScript could be the most widely used programming language in the world, but for many developers, its modern version looks very different from what they first learned. With the advent of ECMAScript ...

The JavaScript innovation train is really picking up momentum lately, driven—as always—by the creativity of the JavaScript developer community. The emerging local-first SQL datastores crystalize ideas ...

Nearly two years after Google DeepMind released an updated AlphaFold3 geared at drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, announced an even more powerful ...

The unified JavaScript runtime standard is an idea whose time has come. Here’s an inside look at the movement for server-side JavaScript interoperability. The WinterCG community group was recently ...

Nearly two years after Google DeepMind released AlphaFold 3, an updated version of its system for predicting protein structure that is geared towards drug discovery, its biopharmaceuticals spin-off, ...

The unveiling of the Isomorphic Labs Drug Design Engine (IsoDDE) represents a fundamental shift from merely predicting the shape of biological life to actively engineering its functions. While ...

Read more: Why Switzerland stopped short of formally sanctioning Ukraine Iran war sparks interest in turning Swiss bunkers into data centres Read more: Iran war sparks interest in turning Swiss ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Isomorphic Labs, a subsidiary of Alphabet Inc., is trying to use artificial intelligence to understand biology and transform the way new medicines are discovered and developed. Bloomberg's Tom ...